President Donald Trump announced Wednesday that he has selected Dr. Heidi Overton to serve as the commissioner of the Food and Drug Administration. Overton, a medical doctor currently serving as a deputy director of the White House Domestic Policy Council, has emerged as a key figure in the administration, actively championing the president’s health policy agenda.
In a post on Truth Social, Trump praised Overton as a “rockstar” who is both smart and respected. He expressed confidence that she would advance his core priorities, including the acceleration of medical cures, fostering innovation, reducing drug costs, and securing victories for the “Make America Healthy Again” (MAHA) movement led by Health Secretary Robert F. Kennedy Jr. Kennedy echoed this support on X, highlighting her “exceptional judgment, professionalism, discipline and an unwavering commitment to the American people.”
Overton’s path to confirmation in a narrowly Republican-led Senate appears challenging. Sen. Bill Cassidy, a Louisiana physician who chairs the Senate Health, Education, Labor and Pensions Committee, voiced “strong concerns” regarding the nomination. While acknowledging her medical background, Cassidy cited her limited managerial experience and her involvement in a recent controversial vaccine order—which he described as “almost disqualifying”—as primary reasons for his hesitation. The order in question directed the splitting of the combined measles, mumps and rubella (MMR) vaccine into three separate doses, a move that contradicts the guidance of major medical organizations.
Democratic opposition has been swift and sharp. Washington Sen. Patty Murray, a member of the committee, labeled the nominee a “far-right, anti-abortion extremist” who is unfit to lead the agency. Overton has previously expressed criticism of abortion-inducing medications, and if confirmed, she would be in a position to potentially roll back FDA regulations that have expanded access to these drugs. Mifepristone, often used in combination with misoprostol for medication abortions, accounts for nearly two-thirds of U.S. abortions and is considered by medical professionals to be among the safest medications ever approved by the FDA.
Overton’s professional background includes medical school at the University of New Mexico and a doctorate in clinical investigation from Johns Hopkins University. Before her current White House role, she served as chief policy officer at the America First Policy Institute. Her tenure has already seen her involved in high-profile projects, such as “most favored nation” drug pricing deals and the aforementioned vaccine directive, during which she appeared alongside the president as he suggested a link between vaccine timing and autism—a claim that contradicts decades of scientific research.
The incoming commissioner will inherit a complex landscape left by the previous head, Dr. Marty Makary, who resigned in May. Makary’s departure left several initiatives unfinished, including work on antidepressants, COVID-19 vaccines, and the regulation of ultraprocessed foods. His tenure was marked by friction with industry executives, anti-abortion activists, and internal agency experts, particularly regarding the regulation of flavored e-cigarettes and the approval processes for biotech drugs. Several of his deputies, including vaccine and biotech chief Dr. Vinay Prasad and acting drug center director Dr. Tracy Beth Hoeg, also exited the agency amid intense scrutiny of their work on widely used therapies.
Beyond the political and industry pressures, Overton faces skepticism from within the MAHA movement itself. Activist Kelly Ryerson, known as “Glyphosate Girl,” expressed alarm after a White House roundtable in April, claiming that Overton repeated talking points from pesticide manufacturer Bayer. Ryerson stated she was “stunned by the blatant, undisguised corruption” she witnessed during the event. These internal tensions, combined with the FDA’s recent implementation of extra hurdles for vaccine testing and the blocking of research into COVID-19 shot effectiveness, underscore the difficult balancing act awaiting the new nominee. The report also notes that she stood by Trump as he falsely suggested the number or timing of vaccines could play a role in rising rates of autism spectrum disorder, at an Oval Office event to promote that order. The report also notes that scientific consensus and decades of studies have firmly concluded there is no link. The report also notes that if confirmed, would be positioned to roll back FDA rules that made them more accessible, overton has been critical of abortion pills and. The report also notes that abortion opponents have expressed frustration that the administration has not acted to stem the flow of such pills prescribed online, a situation they view as undermining state abortion bans. The report also notes that makary’s replacement will face challenges he left behind. The report also notes that but sweet-flavored vapes have long been blamed for the trend of teenage vaping, reynolds are seeking to market to adult smokers. The report also notes that fDA scientists have hesitated to endorse those products to curb adult smoking.
Comments